<div id="readability-page-1"><p>Jamison Private Wealth Management, Inc. disclosed a purchase of Johnson &amp; Johnson shares valued at $6,762,412 in its SEC filing for the period ended Q3 2025, submitted on October 14, 2025.</p><p>Increased position by 39,471 shares, with an estimated trade value of $6.76 million based on the quarter’s average price</p><p>Trade represents a 0.86% change relative to the fund’s 13F reportable assets under management</p><p>Post-trade, the fund holds 87,545 shares of Johnson &amp; Johnson valued at $16.23 million as of September 30, 2025.</p><p>The stake now accounts for 2.06% of Jamison Private Wealth Management’s reportable AUM, which places it outside the fund's top five holdings</p><h2 id="what-happened">What happened</h2><p>According to a filing with the Securities and Exchange Commission (SEC) dated October 14, 2025, Jamison Private Wealth Management, Inc. increased its holdings in <strong>Johnson &amp; Johnson</strong> <span>(JNJ<span> 0.45%</span>)</span> by 39,471 shares during Q3 2025. The estimated value of shares acquired, based on the average closing price for the quarter, is $6.76 million. The fund’s total position in the company at quarter-end stood at 87,545 shares.</p><h2 id="what-else-to-know">What else to know</h2><p>This purchase brings the Johnson &amp; Johnson stake to 2.06% of the fund’s $789.50 million reportable AUM as of September 30, 2025</p><p>Top holdings following the quarter-end are:</p><p>NASDAQ:NVDA: $35.51 million (4.5% of AUM) as of September 30, 2025</p><p>NASDAQ:AAPL: $34.23 million (4.3% of AUM) as of September 30, 2025</p><p>NASDAQ:MSFT: $33.25 million (4.2% of AUM) as of September 30, 2025</p><p>NYSE:VMC: $24.17 million (3.1% of AUM) as of September 30, 2025</p><p>NYSE:JPM: $17.55 million (2.2% of AUM) as of September 30, 2025</p><p>As of October 13, 2025, shares were priced at $190.90, up 18.1% over the past year ending October 13, 2025, outperforming the S&amp;P 500 by 7.65 percentage points over the past year</p><p>Johnson &amp; Johnson reported trailing twelve-month revenue of $90.63 billion and net income of $22.66 billion for the twelve months ended June 29, 2025</p><p>The stock’s annualized dividend yield stood at 2.70% as of October 14, 2025, with shares 2.86% below their 52-week high as of October 14, 2025</p><h2 id="company-overview">Company overview</h2><div><table><tbody><tr><th>Metric</th><th>Value</th></tr><tr><td>Revenue (TTM)</td><td>$90.63 billion</td></tr><tr><td>Net Income (TTM)</td><td>$22.66 billion</td></tr><tr><td>Dividend Yield</td><td>2.70%</td></tr><tr><td>Price (as of market close October 13, 2025)</td><td>$190.90</td></tr></tbody></table></div><h2 id="company-snapshot">Company snapshot</h2><p>Offers a diversified portfolio of pharmaceuticals, and medical devices.</p><p>Generates revenue primarily through the development, manufacturing, and global sale of prescription medicines, surgical and medical devices, and over-the-counter consumer healthcare products.</p><p>Serves healthcare professionals, hospitals, wholesalers, retailers, and the general public worldwide.</p><p>Johnson &amp; Johnson is a global healthcare leader with a broad product base spanning pharmaceuticals, MedTech, and consumer health. Its scale, established brands, and focus on research and development underpin a strong competitive position in the industry.</p><h2 id="foolish-take">Foolish take</h2><p>Jamison Private Wealth Management is more than a little enthusiastic about Johnson &amp; Johnson. The pharmaceutical and medical device giant made up 2.1% of its portfolio at the end of September. At the end of June it was a 1.1% position. </p><p>Johnson &amp; Johnson isn't a top-five holding but it's up there. It was the fund's eigth largest holding at the end of the third quarter. </p><p>Jamison's Johnson &amp; Johnson position is working out well for the firm. The stock has more than doubled the benchmark <strong>S&amp;P 500</strong> index's performance this year with a gain of about 33% as of Oct. 16, 2025.</p><p>Spinning off its slow growing consumer health division in 2023 has had the intended effect on Johnson &amp; Johnson's growth rate. Third-quarter sales rose 6.8% year over year. Encouraged by the recently strong performance, management recently raised its sales estimate for 2025 to $93.7 billion, which represents a 5.7% gain.</p><h2 id="glossary">Glossary</h2><p><strong>AUM (Assets Under Management):</strong> The total market value of investments managed on behalf of clients by a fund or firm.<br/><strong>13F reportable assets:</strong> Securities that investment managers must disclose in quarterly SEC filings if they exceed $100 million in U.S. equity assets.<br/><strong>Dividend yield:</strong> Annual dividends per share divided by the share price, shown as a percentage.<br/><strong>Trailing twelve months (TTM):</strong> The 12-month period ending with the most recent quarterly report.<br/><strong>Outperforming the S&amp;P 500:</strong> Achieving a higher return than the S&amp;P 500 index over a specified period.<br/><strong>Stake:</strong> The ownership interest or amount of shares held in a company by an investor or fund.<br/><strong>Quarter-end:</strong> The last day of a fiscal quarter, used as a reference point for financial reporting.<br/><strong>Reportable AUM:</strong> The portion of assets under management that must be disclosed in regulatory filings.<br/><strong>Annualized:</strong> Converted to a yearly rate based on data from a shorter period, for comparison purposes.<br/><strong>Top holdings:</strong> The largest investments in a fund’s portfolio, ranked by value or percentage of total assets.<br/><strong>MedTech:</strong> Medical technology sector, including devices, equipment, and solutions for healthcare.<br/></p>                                                                            </div>

<p>Jamison Private Wealth Management, Inc. has increased its stake in Johnson & Johnson by purchasing 39,471 shares valued at approximately $6.76 million, as disclosed in an SEC filing dated October 14, 2025. This acquisition raises the fund's total holdings in J&J to 87,545 shares, accounting for 2.06% of its $789.50 million assets under management. The stock has performed well, gaining 33% year-to-date, significantly outperforming the S&P 500. Johnson & Johnson reported trailing twelve-month revenue of $90.63 billion and a net income of $22.66 billion as of June 29, 2025.</p>

Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase